The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition

Journal:: Cancer Research
Published:: 2026-05-01
DOI:: 10.1158/0008-5472.can-25-2764
Affiliations:: 1
Authors:: 13

Go to article

Institutions	Authors	Share
Kura Oncology, Inc., United States of America (USA)	13.000000 13.000000	1.00

Interested in Oncology and Carcinogenesis?

Research leaders

2026 Research Leaders

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their output in Nature Index journals in 2025.

Access free

Latest supplement

Nature Index 2026 Regenerative medicine

Regenerative medicine has the potential to transform the treatment of chronic and life-threatening diseases. But major challenges remain, such as overcoming immune rejection and ensuring that new therapies are developed using more inclusive data sets. In this supplement, we explore the discoveries that are driving the field, the barriers that could limit its progress, and the teams and institutions that are making their mark.

Access free

Nature Index 2026 Nanoscience and nanotechnology

From programmable RNA architectures to next-generation materials for energy and healthcare, researchers are harnessing the unusual properties of the nanoscale to tackle some of society's biggest challenges. This supplement explores the discoveries that are driving the field, the hurdles that remain and the institutions that are leading in nanoscience and nanotechnology research.

Access free

Research highlights of partners

Overexcitable neurons lead to autistic-like behaviours in mice

Institute for Basic Science (IBS)
30 Nov 2023
New doping method boosts solar cell efficiency

Southern University of Science and Technology (SUSTech)
30 Nov 2023
Ants’ venom contains neurotoxins

The University of Queensland (UQ)
31 Oct 2023

Research highlights